Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery



Status:Recruiting
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/31/2019
Start Date:July 22, 2014

Use our guide to learn which trials are right for you!

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

This randomized phase II trial studies how well dabrafenib and trametinib work in treating
patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf
proto-oncogene, serine/threonine kinase (BRAF) mutation. Dabrafenib and trametinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. To compare progression-free survival with intermittent dosing and continuous dosing of
dabrafenib and trametinib among patients with metastatic BRAF V600E/K mutant melanoma.

SECONDARY OBJECTIVES:

I. To estimate the frequency and severity of toxicities of the two dosing schedules.

II. To compare the frequency and severity of fever >= grade 1 per Common Terminology Criteria
for Adverse Events (CTCAE) 4.0 of the two dosing schedules.

III. To compare the response rate (complete and partial response, confirmed and unconfirmed),
overall survival, and survival after progression between the two dosing schedules on step 2.

TRANSLATIONAL MEDICINE OBJECTIVES:

I. To evaluate whether acquired molecular events leading to reactivation of the MAPK pathway
are more common among patients on the continuous dosing arm than on the intermittent dosing
arm using circulating tumor deoxyribonucleic acid (DNA) (ctDNA).

II. To assess the prognostic association between baseline biomarkers and early molecular
events with progression free survival (PFS).

III. To explore the potential interaction between treatment arm and baseline biomarkers/early
molecular events with PFS.

IV. To bank tissue and whole blood in anticipation of future studies to evaluate molecular
events associated with clinical benefit and disease progression in patients treated with
continuous versus intermittent dabrafenib and trametinib.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I (CONTINUOUS DOSING): Patients receive dabrafenib orally (PO) twice daily (BID) and
trametinib PO once daily (QD) on days 1-56. Courses repeat every 56 days in the absence of
disease progression or unacceptable toxicity.

ARM II (INTERMITTENT DOSING): Patients receive dabrafenib PO BID and trametinib PO QD on days
1-7 and 29-56. Courses repeat every 56 days in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for 3 years and
then yearly for 2 years.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed stage IV or unresectable
stage III BRAF V600E or BRAF V600K mutant melanoma

- Patients must have BRAF V600E or BRAF V600K mutation identified by a Clinical
Laboratory Improvement Amendments (CLIA)-certified laboratory; acceptable analytic
techniques include but are not restricted to DNA sequencing, pyrosequencing,
polymerase chain reaction (PCR), melting point assays, and immunohistochemistry

- Contrast-enhanced computed tomography (CT) scans of the neck, chest, abdomen and
pelvis are required; a whole body positron emission tomography (PET)/CT scan with
diagnostic quality images and intravenous iodinated contrast may be used in lieu of a
contrast enhanced CT of the neck, chest, abdomen and pelvis; contrast may be omitted
if the treating investigator believes that exposure to contrast poses an excessive
risk to the patient; patients must have measurable disease per Response Evaluation
Criteria in Solid Tumors (RECIST) 1.1; all measurable lesions must be assessed within
28 days prior to registration; tests to assess non-measurable disease must be
performed within 42 days prior to registration; all disease must be assessed and
documented on the Baseline Tumor Assessment Form (RECIST 1.1)

- Patients must not have received a prior BRAF or mitogen-activated protein kinase
kinase (MEK) inhibitor

- Patients with a history of brain metastases are eligible if the patient is
asymptomatic with no residual neurological dysfunction and has not received
enzyme-reducing anti-epileptic drugs or corticosteroids for at least 7 days prior to
registration

- Patients must not have received any anti-cancer drug within 28 days prior to
registration, and must not have received any nitrosoureas or mitomycin C within 42
days prior to registration

- Patients must not have received any major surgery or immunotherapy within 28 days
prior to registration

- Patients must not have any unresolved toxicity greater than National Cancer Institute
(NCI)-CTCAE version (v) 4.0 grade 1 from previous anti-cancer therapy except alopecia
within 7 days prior to registration

- Absolute neutrophil count (ANC) >= 1,200/ul (obtained within 28 days prior to
registration)

- Platelets >= 100,000/ul (obtained within 28 days prior to registration)

- Hemoglobin >= 9 g/dL (obtained within 28 days prior to registration)

- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (or =< 2.5 x upper
limit of normal [ULN] with Gilbert's syndrome) (obtained within 28 days prior to
registration)

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or
< 5 x IULN for patients with known liver metastases) (obtained within 28 days prior to
registration)

- Serum albumin >= 2.5 g/dL (obtained within 28 days prior to registration)

- Serum creatinine =< 1.5 x mg/dL OR measured or calculated creatinine clearance >= 50
mL/min; creatinine measurements must be obtained within 28 days prior to registration

- Patients must have lactate dehydrogenase (LDH) obtained within 28 days prior to
registration in order to obtain baseline stratification information

- Patients must have a left ventricular ejection fraction (LVEF) >= institutional lower
limit of normal (ILLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
within 28 days prior to registration

- Patients must have corrected QT (QTc) =< 480 msec by electrocardiogram (ECG)
(corrected using the Bazett's formula) within 28 days prior to registration

- Patients with known history or current evidence of retinal vein occlusion (RVO) or
central serous retinopathy (CSR) are not eligible:

- History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled
glaucoma or ocular hypertension, uncontrolled systemic disease such as
hypertension, diabetes mellitus, or history of hyperviscosity or
hypercoagulability syndromes)

- Visible retinal pathology as assessed by ophthalmic exam that is considered a
risk factor for RVO or CSR such as:

- Evidence of new optic disc cupping

- Evidence of new visual field defects

- Intraocular pressure > 21 mmHg

- NOTE: ophthalmic exam is required for all patients; exam must be obtained within
28 days prior to registration

- Patients must be able to take oral medications; patients must not have any impairment
of gastrointestinal function or gastrointestinal disease that may significantly alter
the absorption of protocol treatment (e.g. ulcerative disease, uncontrolled nausea,
vomiting, diarrhea, malabsorption syndrome or small bowel resection)

- Patients receiving anticoagulation treatment are allowed to participate with
international normalized ratio (INR) established within the therapeutic range

- Patients must not have a history of pneumonitis or interstitial lung disease

- Patients must not have any grade II/III/IV cardiac disease as defined by the New York
Heart Association criteria (i.e., patients with cardiac disease resulting in marked
limitation of physical activity or resulting in inability to carry on any physical
activity without discomfort), unstable angina pectoris, myocardial infarction within 6
months, or serious uncontrolled cardiac arrhythmia; abnormal cardiac valve morphology
(>= grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e.,
mild regurgitation/stenosis]) can be entered on study; patients with a history of
atrial fibrillation must have atrial fibrillation controlled for at least 30 days
prior to registration

- Patients with known hepatitis B or hepatitis C are not eligible, regardless of
concomitant antiretroviral therapy or current viral load

- Patients with known human immunodeficiency virus (HIV) may be eligible providing they
meet the following additional criteria:

- Cluster of differentiation (CD)4 cells >= 500/uL

- Serum HIV viral load of < 25,000 IU/ml

- No current antiretroviral therapy

- Tests must be obtained within 28 days prior to registration; patients who
are HIV positive (+) and do not meet all of these criteria are not eligible
for this study (HIV/hepatitis testing are not required for patients without
known infection)

- Pre-study history and physical must be obtained with 28 days prior to registration

- Patients must have dermatology exam obtained within 28 days prior to registration to
obtain baseline measurement; exam to be performed by treating physician or designated
dermatologist

- Patients must have Zubrod performance status of 0, 1 or 2

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for three years; exception:
patients with known history of colon cancer, cancer of the pancreas, or any cancer
known to harbor an activating RAS mutation are ineligible regardless of stage or time
since diagnosis

- Patients must not be pregnant or nursing; women/men of reproductive potential must
have agreed to use an effective contraceptive method; a woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months; in addition to routine contraceptive methods, "effective
contraception" also includes heterosexual celibacy and surgery intended to prevent
pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures; hormonal contraception is not
allowed

- Patients must be offered the opportunity to participate in specimen banking

- Patients with cutaneous or superficial lesions that do not require imaging guidance
for biopsy must be willing to undergo biopsies for tissue submission and blood draws
for translational medicine

- Patients or their legally authorized representative must be informed of the
investigational nature of this study and must sign and give written informed consent
in accordance with institutional and federal guidelines

- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system

- STEP 2: RANDOMIZATION

- After completing one cycle of therapy, patients will be registered for randomization
between intermittent and continuous dosing, provided that they were eligible for the
initial step 1 registration and satisfy the following criteria

- Patients must not have unequivocal disease progression (by RECIST v1.1) during the
first cycle; patients must have disease assessed using the same method as baseline
within +/- 5 days of the day 56 scheduled assessment (between days 51-55 of cycle 1,
or days 1-5 of cycle 2); all disease must be assessed and documented on the follow-up
tumor assessment form (RECIST 1.1)

- Patients must be registered to step 2: randomization within +/- 5 days of starting
cycle 2; patients MUST NOT be registered prior to the day 56 disease assessment
We found this trial at
754
sites
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 800-328-6010
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Peter Rubin
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
?
mi
from
Augusta, ME
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Michael A. Schwartz
Phone: 954-267-7750
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Natale T. Sheehan
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Rangaswamy Govindarajan
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
?
mi
from
Seattle, WA
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Principal Investigator: John A. Keech
Phone: 907-458-5380
?
mi
from
Yakima, WA
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-486-6000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-487-7447
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-678-9000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-539-2273
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
?
mi
from
Adrian, MI
Click here to add this to my saved trials
Altamonte Springs, Florida 32701
Principal Investigator: Carlos A. Alemany
Phone: 888-823-5923
?
mi
from
Altamonte Springs, FL
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
Principal Investigator: Brian P. Tudor
Phone: 435-688-4167
?
mi
from
American Fork, UT
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Ames, IA
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
?
mi
from
Anacortes, WA
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Han A. Koh
Phone: 800-398-3996
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
Principal Investigator: John E. Doster
Phone: 864-512-4651
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Christopher D. Lao
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Tatjana Kolevska
Phone: 877-642-4691
?
mi
from
Antioch, CA
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Christopher H. Chay
Phone: 800-506-2550
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Christopher H. Chay
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-650-8037
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Ragini R. Kudchadkar
Phone: 404-778-1868
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 907-458-5380
?
mi
from
Auburn, WA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Steven R. Schuster
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Yujie Zhao
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Michael A. Schwartz
Phone: 305-674-2625
?
mi
from
Aventura, FL
Click here to add this to my saved trials
Bainbridge Island, Washington 98110
Principal Investigator: John A. Keech
Phone: 907-458-5380
?
mi
from
Bainbridge Island, WA
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Baker City, OR
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Han A. Koh
Phone: 800-398-3996
?
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Mei Tang
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Principal Investigator: Diwakar Davar
Phone: 412-692-2001
?
mi
from
Beaver, PA
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Beavercreek, OH
Click here to add this to my saved trials
118 Northport Avenue
Belfast, Maine 04915
Principal Investigator: Peter Rubin
Phone: 207-338-2500
?
mi
from
Belfast, ME
Click here to add this to my saved trials
Bellevue, Washington 98004
Principal Investigator: John A. Keech
Phone: 907-458-5380
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Bellevue, Washington 98005
Principal Investigator: Gary E. Goodman
Phone: 206-215-3962
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Han A. Koh
Phone: 800-398-3996
?
mi
from
Bellflower, CA
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Gary E. Goodman
Phone: 360-715-4133
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Gary E. Goodman
Phone: 541-706-2909
?
mi
from
Bend, OR
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Christina E. Brzezniak
Phone: 301-319-2100
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Biddeford, Maine 04005
Principal Investigator: Peter Rubin
?
mi
from
Biddeford, ME
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
?
mi
from
Billings, MT
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Robert M. Conry
Phone: 205-934-0220
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boardman, Ohio 44512
Principal Investigator: Howard M. Gross
Phone: 330-629-7500
?
mi
from
Boardman, OH
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Boone, IA
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Adam Lerner
Phone: 617-638-8265
?
mi
from
Boston, MA
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Boulder, CO
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Phone: 888-203-7267
?
mi
from
Brainerd, MN
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
?
mi
from
Branson, MO
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
?
mi
from
Brewer, ME
Click here to add this to my saved trials
Brick, New Jersey 08724
?
mi
from
Brick, NJ
Click here to add this to my saved trials
Bristol, Tennessee 37620
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
?
mi
from
Bristol, TN
Click here to add this to my saved trials
Bristol, Tennessee 37620
Principal Investigator: Asheesh Shipstone
Phone: 423-224-5593
?
mi
from
Bristol, TN
Click here to add this to my saved trials
Bristol, Virginia 24201
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
?
mi
from
Bristol, VA
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bryan, TX
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Gary E. Goodman
Phone: 818-847-4793
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Burien, WA
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Christopher P. Tretter
Phone: 781-744-8027
?
mi
from
Burlington, MA
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Thomas J. Saphner
Phone: 414-302-2304
?
mi
from
Burlington, WI
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials